Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates.
Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next.
What is Structure Therapeutics, and why does GPCR trade like a headline detector?
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for metabolic diseases, with its current spotlight firmly on obesity.
In plain English: unlike injectable peptide drugs (the current giants of weight management), Structure is trying to make pill-form therapies that can scale more easily, broaden access, and potentially combine well with other metabolic drugs. That “pill race” is now being validated at the highest level—regulators. Reuters+1
The big catalyst still powering GPCR: aleniglipron (GSBR-1290) ACCESS program results
The stock’s December narrative began with topline clinical data from ACCESS, Structure’s Phase 2 program for aleniglipron (GSBR-1290)—a once-daily oral, nonpeptide small-molecule GLP‑1 receptor agonist (a well-validated class for weight loss and diabetes).
Key topline numbers (as disclosed by the company)
Structure reported (Dec. 8, 2025):
- In the core Phase 2b ACCESS study, aleniglipron achieved a placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg at 36 weeks (p<0.0001).
- Across all active arms in ACCESS, the company reported a 10.4% adverse event–related treatment discontinuation rate.
- In the exploratory ACCESS II study, the company reported placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) at 240 mg at 36 weeks (p<0.0001).
- Management emphasized a lack of apparent weight-loss plateau by Week 36 at higher doses and described the off-target safety profile as “compelling,” while noting tolerability consistent with the GLP‑1 class. GlobeNewswire
Those numbers matter because the obesity market has become a comparative sport: investors line up efficacy, tolerability, and discontinuation rates—then handicap whether a drug can win share, command reimbursement, or become a partnership/M&A asset.
Structure’s December financing: from a proposed deal to a $747.5M close
Right after the clinical-data wave, Structure moved to strengthen its balance sheet—an event that can be both reassuring (more runway) and dilutive (more shares) for shareholders.
Pricing details (Dec. 9–10, 2025)
The company announced pricing for an upsized public offering including:
- 8,461,538 ADSs priced at $65.00 per ADS
- Pre-funded warrants to purchase 1,538,462 ADSs priced at $64.9999 per warrant
- Expected gross proceeds of ~$650 million (before discounts/expenses), with a 30-day underwriter option for up to 1,500,000 additional ADSs
Closing details (Dec. 11, 2025)
Structure later announced it closed an upsized offering of 9,961,538 ADSs (including the underwriters’ option) plus the same 1,538,462 pre-funded warrants, for gross proceeds of about $747.5 million (before fees/expenses).
Why this matters for the stock: Late-stage obesity trials are expensive. A large raise can reduce near-term financing risk—but it can also cap upside temporarily as markets digest dilution. The balance between those forces often sets the “new normal” trading range.
New pipeline news: Structure starts Phase 1 for oral amylin program (ACCG-2671)
On Dec. 17, 2025, Structure announced it initiated a first-in-human Phase 1 study for ACCG‑2671, its lead oral small-molecule amylin receptor agonist program aimed at obesity.
Key points the company disclosed:
- The Phase 1 study is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic activity in healthy volunteers and individuals with obesity, using single-ascending and multiple-ascending dose cohorts.
- Structure described ACCG‑2671 as a DACRA (dual amylin and calcitonin receptor agonist), and said it is also advancing ACCG‑3535 (a second DACRA with a distinct chemical structure) alongside other amylin approaches in preclinical development.
Investor read-through: GLP‑1s may be the “engine,” but the market increasingly cares about next-generation combinations (for more fat loss, better tolerability, and lean-mass preservation). A second clinical program can broaden optionality—especially if oral combinations become commercially feasible.
Analyst forecasts and price targets as of Dec. 23, 2025
Analyst forecasts have been moving quickly after the ACCESS data and financing.
Recent highlighted analyst move (Dec. 22, 2025)
H.C. Wainwright raised its price target to $90 from $60 and maintained a Buy rating, citing encouraging Phase 2 data and validating the company’s titration strategy. The note also discussed a potential Phase 3 efficacy range and emphasized the competitive dynamics in oral GLP‑1s.
Consensus targets (numbers vary by data provider)
Because different platforms pull from different analyst sets and timing, you’ll see slightly different consensus figures:
- MarketBeat lists an average target around $99.11 with a “Moderate Buy” consensus based on 14 analyst ratings, with targets spanning roughly $65 to $125. MarketBeat
- StockAnalysis shows a “Strong Buy” consensus with an average target around $97.9, with targets ranging $65 to $125, and highlights multiple December target increases from major firms. StockAnalysis
- A Nasdaq-hosted Fintel write-up (Dec. 21) pegged an average one-year price target around $94.31, citing a revised analyst target set with a stated low/high range (about $60.60 to $131.25).
What analysts are implicitly underwriting
Across notes and target changes, the same drivers keep repeating:
- Can aleniglipron’s Phase 2 weight loss translate to Phase 3 durability and tolerability?
- Does oral administration unlock a commercial scale advantage versus injectable supply constraints?
- Does Structure become a strategic asset in a market where big pharma is paying up for obesity pipelines?
That last point isn’t theoretical. In 2025, Pfizer completed its acquisition of obesity biotech Metsera in a deal structure valued up to $10 billion (cash plus contingent milestone payments), highlighting how aggressively large pharma has been shopping for obesity exposure.
Dec. 23, 2025 industry shockwave: FDA approves Novo Nordisk’s Wegovy pill
One of the biggest obesity-market developments on Dec. 23, 2025 came from outside Structure itself: Reuters reported that the U.S. FDA approved Novo Nordisk’s Wegovy pill, giving Novo a first-mover advantage in oral obesity treatment. Reuters also noted that companies including Structure (GPCR.O) are among those testing oral weight-loss drugs.
A separate Reuters factbox published the same day emphasized why this matters:
- Pills are generally easier to manufacture and may avoid some supply issues seen early in injectable rollouts.
- Structure’s mid-stage program showed up to 11.3% weight loss after 36 weeks in a 230-person trial, and the company planned late-stage development after an FDA meeting expected in the first half of 2026.
For GPCR investors, this is a double-edged signal:
- Positive: The FDA is now explicitly validating the category (“oral obesity pill” is real, regulated, and commercial).
- Challenging: The competitive bar rises, and comparisons will increasingly be made against approved oral options—not just against experimental peers.
Dec. 23, 2025 valuation analysis: “Is GPCR expensive now?”
A Dec. 23 analysis from Simply Wall St framed the recent surge through a valuation lens, noting the stock’s sharp run-up over the past month/quarter and discussing whether a higher price-to-book multiple can be justified for a clinical-stage obesity story.
Whether you agree with that framework or not, it reflects a real market shift: GPCR is no longer priced like a sleepy R&D option—it’s priced like a contender in a trillion-dollar public health problem.
Where GPCR stands on Dec. 23, 2025: price, volatility, and the “post-data” reality
GPCR has been highly volatile since the ACCESS readout. As of Dec. 23, 2025 trading data, shares were around $67–$68, with an intraday range roughly $63.25 to $67.52 in the finance tape used here.
For longer-range context, Barchart data shows GPCR’s 52-week range included lows around $13.22 and highs near $94.90 (with the high marked on Dec. 8, 2025—around the ACCESS news).
That spread is your reminder: in clinical-stage biotech, the chart is mostly a referendum on future trial confidence.
What to watch next: the 2026 catalysts that could move Structure Therapeutics stock
Based on company disclosures and industry reporting, the next major inflection points investors typically focus on include:
- Regulatory alignment for Phase 3: Structure has pointed toward advancing aleniglipron into Phase 3, and Reuters reporting references an FDA meeting expected in the first half of 2026 ahead of late-stage plans.
- Phase 1 readouts for ACCG‑2671: Early safety/tolerability and PK/PD signals can matter, especially if the market starts valuing oral combination potential.
- How the post-financing balance sheet translates into execution speed: the large December raise reduces near-term funding pressure but increases expectations for crisp trial operations.
- Competitive news flow in oral obesity: with Novo’s Wegovy pill approved and other programs progressing, comparisons will only intensify.
Risks investors should keep on the table (because biotech is allergic to certainty)
Even with strong Phase 2 data, several risk buckets remain central for GPCR:
- Clinical translation risk: Phase 2 outcomes may not replicate in larger, longer, more diverse Phase 3 populations.
- Tolerability and discontinuation: obesity drugs are long-duration therapies; tolerability can decide commercial winners as much as weight-loss percentage.
- Competitive pressure: the oral obesity field is getting crowded—and now includes an FDA-approved oral entrant.
- Financing/dilution dynamics: the company raised substantial capital in December; future raises are still possible in biotech, depending on burn and trial scope.
Bottom line on Dec. 23, 2025
Structure Therapeutics stock is being shaped by a powerful mix of credible Phase 2 weight-loss data, a strengthened balance sheet following a large public offering, and expanding investor belief that oral obesity therapy is becoming a real commercial category—a thesis dramatically reinforced today by Novo Nordisk’s FDA win for a Wegovy pill.
At the same time, the new FDA approval raises the competitive standard—and the next phase of GPCR’s story will likely be written in Phase 3 trial design, execution, and durability/tolerability evidence.
